Hyperleukocytosis in Solid Tumors: a Rare Paraneoplastic Syndrome Associated with Poor Prognosis

Detalhes bibliográficos
Autor(a) principal: Ferrão, J
Data de Publicação: 2021
Outros Autores: Sardinha, M, Dutra, E
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10400.17/4641
Resumo: Hematological paraneoplastic syndromes are fairly uncommon. While mild leukocytosis in solid tumors is well reported, white blood cell (WBC) count over 50,000 u/L, described as paraneoplastic leukemoid reaction (PLR), is not. Indeed, when found, it is usually associated with a higher burden of disease, tumor activity and worse clinical outcomes. We report the case of a challenging and burdensome diagnosis of a presumptive hematological paraneoplastic syndrome in a patient with a locally advanced lung cancer admitted in the Internal Medicine ward. After the end of chemotherapy, clinical and laboratory benefit was observed; however, the aggressive course of the disease became clear, with progression and downhill course that was unresponsive to treatment.
id RCAP_bf1ad82988e6df014fa92784b69c98c2
oai_identifier_str oai:repositorio.chlc.min-saude.pt:10400.17/4641
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Hyperleukocytosis in Solid Tumors: a Rare Paraneoplastic Syndrome Associated with Poor PrognosisCHLC MEDHSAC ONCCHLC ANPATAntineoplastic Agents / therapeutic useCarcinoma / complications*Carcinoma / drug therapyFatal OutcomeHumansMaleMiddle AgedLung Neoplasms / complications*Lung Neoplasms / drug therapyParaneoplastic Syndromes / diagnosis*Paraneoplastic Syndromes / pathology*PrognosisHematological paraneoplastic syndromes are fairly uncommon. While mild leukocytosis in solid tumors is well reported, white blood cell (WBC) count over 50,000 u/L, described as paraneoplastic leukemoid reaction (PLR), is not. Indeed, when found, it is usually associated with a higher burden of disease, tumor activity and worse clinical outcomes. We report the case of a challenging and burdensome diagnosis of a presumptive hematological paraneoplastic syndrome in a patient with a locally advanced lung cancer admitted in the Internal Medicine ward. After the end of chemotherapy, clinical and laboratory benefit was observed; however, the aggressive course of the disease became clear, with progression and downhill course that was unresponsive to treatment.ElsevierRepositório do Centro Hospitalar Universitário de Lisboa Central, EPEFerrão, JSardinha, MDutra, E2023-08-11T14:44:26Z2021-082021-08-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.17/4641engAm J Med Sci . 2021 Aug;362(2):211-21410.1016/j.amjms.2021.01.027info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-08-13T06:03:20Zoai:repositorio.chlc.min-saude.pt:10400.17/4641Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T20:26:58.257202Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Hyperleukocytosis in Solid Tumors: a Rare Paraneoplastic Syndrome Associated with Poor Prognosis
title Hyperleukocytosis in Solid Tumors: a Rare Paraneoplastic Syndrome Associated with Poor Prognosis
spellingShingle Hyperleukocytosis in Solid Tumors: a Rare Paraneoplastic Syndrome Associated with Poor Prognosis
Ferrão, J
CHLC MED
HSAC ONC
CHLC ANPAT
Antineoplastic Agents / therapeutic use
Carcinoma / complications*
Carcinoma / drug therapy
Fatal Outcome
Humans
Male
Middle Aged
Lung Neoplasms / complications*
Lung Neoplasms / drug therapy
Paraneoplastic Syndromes / diagnosis*
Paraneoplastic Syndromes / pathology*
Prognosis
title_short Hyperleukocytosis in Solid Tumors: a Rare Paraneoplastic Syndrome Associated with Poor Prognosis
title_full Hyperleukocytosis in Solid Tumors: a Rare Paraneoplastic Syndrome Associated with Poor Prognosis
title_fullStr Hyperleukocytosis in Solid Tumors: a Rare Paraneoplastic Syndrome Associated with Poor Prognosis
title_full_unstemmed Hyperleukocytosis in Solid Tumors: a Rare Paraneoplastic Syndrome Associated with Poor Prognosis
title_sort Hyperleukocytosis in Solid Tumors: a Rare Paraneoplastic Syndrome Associated with Poor Prognosis
author Ferrão, J
author_facet Ferrão, J
Sardinha, M
Dutra, E
author_role author
author2 Sardinha, M
Dutra, E
author2_role author
author
dc.contributor.none.fl_str_mv Repositório do Centro Hospitalar Universitário de Lisboa Central, EPE
dc.contributor.author.fl_str_mv Ferrão, J
Sardinha, M
Dutra, E
dc.subject.por.fl_str_mv CHLC MED
HSAC ONC
CHLC ANPAT
Antineoplastic Agents / therapeutic use
Carcinoma / complications*
Carcinoma / drug therapy
Fatal Outcome
Humans
Male
Middle Aged
Lung Neoplasms / complications*
Lung Neoplasms / drug therapy
Paraneoplastic Syndromes / diagnosis*
Paraneoplastic Syndromes / pathology*
Prognosis
topic CHLC MED
HSAC ONC
CHLC ANPAT
Antineoplastic Agents / therapeutic use
Carcinoma / complications*
Carcinoma / drug therapy
Fatal Outcome
Humans
Male
Middle Aged
Lung Neoplasms / complications*
Lung Neoplasms / drug therapy
Paraneoplastic Syndromes / diagnosis*
Paraneoplastic Syndromes / pathology*
Prognosis
description Hematological paraneoplastic syndromes are fairly uncommon. While mild leukocytosis in solid tumors is well reported, white blood cell (WBC) count over 50,000 u/L, described as paraneoplastic leukemoid reaction (PLR), is not. Indeed, when found, it is usually associated with a higher burden of disease, tumor activity and worse clinical outcomes. We report the case of a challenging and burdensome diagnosis of a presumptive hematological paraneoplastic syndrome in a patient with a locally advanced lung cancer admitted in the Internal Medicine ward. After the end of chemotherapy, clinical and laboratory benefit was observed; however, the aggressive course of the disease became clear, with progression and downhill course that was unresponsive to treatment.
publishDate 2021
dc.date.none.fl_str_mv 2021-08
2021-08-01T00:00:00Z
2023-08-11T14:44:26Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10400.17/4641
url http://hdl.handle.net/10400.17/4641
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Am J Med Sci . 2021 Aug;362(2):211-214
10.1016/j.amjms.2021.01.027
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799133538636791808

Registros relacionados